Physician profile
Roy O Asta
NPI 1205809027
$2,717.42
in general payments reported to CMS, 2019-2025
14 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.09 · 2021: $179 · 2022: $247 · 2023: $889 · 2024: $880 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $564.57 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $506.10 | 2022-2025 | Vraylar |
| Alkermes, INC. | $347.66 | 2021-2023 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $343.10 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $311.66 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $260.75 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.38 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $58.29 | 2021-2025 | |
| Indivior INC. | $57.18 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.94 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $29.54 | 2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $23.09 | 2019 | |
| Biogen, INC. | $20.00 | 2024 | Zurzuvae |
| Corium, LLC | $19.16 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Asta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.